(Total Views: 673)
Posted On: 08/10/2021 1:51:03 PM
Post# of 148903
I’ll bite.
I believe the FDA letter was an effort to stop the multiple
inquires and entreaties from physicians, congressional representatives and shareholders to grant Leronlimab the same consideration given to remdesivir and other minimally effective antiviral and therapeutic treatments.
EUA is designed to authorize treatments which may be effective for life threatening conditions for which effective approved interventions are lacking.
Leronlimab more than meets that threshold, without the deleterious effects of remdesivir or steroids.
Do you have a different understanding of the intent of the FDA letter?
I believe the FDA letter was an effort to stop the multiple
inquires and entreaties from physicians, congressional representatives and shareholders to grant Leronlimab the same consideration given to remdesivir and other minimally effective antiviral and therapeutic treatments.
EUA is designed to authorize treatments which may be effective for life threatening conditions for which effective approved interventions are lacking.
Leronlimab more than meets that threshold, without the deleterious effects of remdesivir or steroids.
Do you have a different understanding of the intent of the FDA letter?
(23)
(1)Scroll down for more posts ▼
